Related Experiment Video
Updated: Jun 20, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
ADCs for colorectal carcinoma: decoding clinical evidence for molecular design innovation
Xiangxin Wu1, Fenqi Du2, Zhenhua Liu1
1Department of Abdominal Surgery, Ganzhou cancer hospital, Ganzhou 341005, Jiangxi Province, PR China.
Abstract:
Antibody-drug conjugate (ADC) is a novel type of targeted systemic therapy that is changing the current landscape of tumor treatment. By integrating the specificity of antibodies with the cytotoxic effects of their payloads, ADCs facilitate precise tumor killing. In solid tumors such as breast cancer, non-small cell lung cancer (NSCLC), and urothelial carcinoma, ADCs have demonstrated significant efficacy with acceptable toxicity profiles. Colorectal cancer (CRC) ranks as the third most prevalent tumor globally, and there remains an unmet clinical need for targeted treatment options. The approval of T-DXd for HER2-positive (IHC3+) CRC marks ADCs' entry into this treatment arena. This article will focus on the clinical performance of ADCs and explore design considerations and future directions for ADCs in CRC. Significance statement ADCs, a targeted treatment strategy that has emerged over the past two decades, are rapidly evolving. we believe that ADCs will offer more targeted treatment options for CRC patients in the future. This review focuses on the clinical performance of ADCs and explores design considerations and future directions for ADCs in CRC. This study provides a reference for researchers to understand and learn ADC.
Insights
Antibody-drug conjugates (ADCs) offer precise tumor killing for various cancers. ADCs are now entering colorectal cancer (CRC) treatment, providing new targeted options for patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) represent a novel targeted therapy integrating antibody specificity with cytotoxic payloads.
- ADCs have shown efficacy in solid tumors like breast cancer, NSCLC, and urothelial carcinoma.
- Colorectal cancer (CRC) has a high global prevalence and an unmet need for targeted therapies.
Purpose of the Study:
- To review the clinical performance of ADCs in colorectal cancer (CRC).
- To explore ADC design considerations for CRC treatment.
- To discuss future directions for ADCs in the CRC therapeutic landscape.
Main Methods:
- Review of clinical data on ADC efficacy and toxicity in solid tumors.
- Analysis of ADC design principles relevant to CRC.
- Exploration of emerging trends and future research in ADCs for CRC.
Main Results:
- ADCs demonstrate significant efficacy and acceptable toxicity in various solid tumors.
- The approval of T-DXd for HER2-positive CRC signifies ADCs' potential in this area.
- ADCs are poised to offer advanced targeted treatment strategies for CRC.
Conclusions:
- ADCs are a rapidly evolving targeted treatment strategy with significant potential for CRC.
- Future research and development in ADC design and application are crucial for improving CRC outcomes.
- This review serves as a reference for understanding ADCs in the context of CRC research.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...